Arena Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Arena Pharmaceuticals's estimated annual revenue is currently $37k per year.
- Arena Pharmaceuticals received $405.7M in venture funding in March 2018.
- Arena Pharmaceuticals's estimated revenue per employee is $185
- Arena Pharmaceuticals's total funding is $390.7M.
- Arena Pharmaceuticals's current valuation is $5.7B. (January 2022)
Employee Data
- Arena Pharmaceuticals has 200 Employees.
- Arena Pharmaceuticals grew their employee count by -33% last year.
Arena Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP - Global Commercial Marketing and Planning | Reveal Email/Phone |
2 | VP, Global Marketing and Planning | Reveal Email/Phone |
3 | Director, Clinical Operations | Reveal Email/Phone |
4 | Senior Director, Nonclinical Development and Clinical Pharmacology | Reveal Email/Phone |
5 | Director, Clinical Operations | Reveal Email/Phone |
6 | Associate Director, Study Recruitment Optimization | Reveal Email/Phone |
7 | Deputy Director Commerce | Reveal Email/Phone |
8 | Senior Director, Atopic Dermatitis Program Lead, Clinical Development | Reveal Email/Phone |
9 | Quality Assurance Manager | Reveal Email/Phone |
10 | Manager GD Training Quality | Reveal Email/Phone |
Arena Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 542 | -3% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1634 | -2% | N/A | N/A |
#10 | $10.5M | 48 | 12% | N/A | N/A |
What Is Arena Pharmaceuticals?
We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with international operations in Zug, Switzerland.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$390.7M
Total Funding
200
Number of Employees
$37k
Revenue (est)
-33%
Employee Growth %
$5.7B
Valuation
N/A
Accelerator
Arena Pharmaceuticals News
Ocuphire Pharma, Inc.: Jay Pepose was appointed chief medical ... after more than four years at Arena Pharmaceuticals where he served as VP...
... Pfizer's acquisition of Arena Pharmaceuticals for $6.7 billion. This is largely seen as a positive for Pfizer, given Arena's robust drug...
Pfizer recently completed a $6.7 billion acquisition of Arena Pharmaceuticals. Pfizer bought Arena Pharmaceuticals to access Etrasimod, an...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to ...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $46.7M | 200 | 3% | N/A |
#2 | $71.5M | 200 | 6% | N/A |
#3 | $7.5M | 201 | 16% | N/A |
#4 | $61.8M | 201 | 25% | N/A |
#5 | $32.2M | 202 | 25% | N/A |
Arena Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-03-24 | $50.0M | Undisclosed | Azimuth Opportunity Ltd | Article |
| 2009-06-18 | $100.0M | Undisclosed | Piper Jaffray and Co | Article |
| 2010-06-04 | $35.5M | Undisclosed | Deerfield Management | Article |
| 2011-03-30 | $35.5M | Undisclosed | Article | |
| 2012-01-12 | $33.0M | Replaces: D | Article | |
| 2012-05-17 | $Undisclosed | Undisclosed | Jefferies & Company Inc, Piper Jaffray & Co | Article |
| 2015-01-22 | $Undisclosed | Undisclosed | Jefferies LLC | Article |
| 2017-04-18 | $79.4M | Undisclosed | Citigroup | Article |
| 2017-07-12 | $150.0M | Undisclosed | Citigroup, Leerink Partners | Article |
| 2018-03-22 | $405.7M | Undisclosed | Multiple | Article |